Which has better earnings and valuation, PGEN or PTCT?

PTC Therapeutics has higher revenue and earnings than Precigen. PTC Therapeutics is trading at a lower price-to-earnings ratio than Precigen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Precigen $9.68M 215.82 -$250.64M -$1.18 N/A PTC Therapeutics $1.73B 4.05 $682.64M -$2.33 N/A

Is PGEN or PTCT more profitable?

PTC Therapeutics has a net margin of -22.58% compared to Precigen's net margin of -646.99%. Precigen's return on equity of 717.50% beat PTC Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Precigen -646.99% 717.50% 58.48% PTC Therapeutics -22.58% -362.45% -6.76%

Does the media prefer PGEN or PTCT?

In the previous week, PTC Therapeutics had 11 more articles in the media than Precigen. MarketBeat recorded 17 mentions for PTC Therapeutics and 6 mentions for Precigen. Precigen's average media sentiment score of 1.20 beat PTC Therapeutics' score of 0.40 indicating that Precigen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Precigen 2 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive PTC Therapeutics 8 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor CNTA or PGEN?

In the previous week, Precigen had 2 more articles in the media than Centessa Pharmaceuticals. MarketBeat recorded 6 mentions for Precigen and 4 mentions for Centessa Pharmaceuticals. Precigen's average media sentiment score of 1.20 beat Centessa Pharmaceuticals' score of 0.73 indicating that Precigen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Centessa Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Precigen 2 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor MIRM or PGEN?

In the previous week, Precigen had 1 more articles in the media than Mirum Pharmaceuticals. MarketBeat recorded 6 mentions for Precigen and 5 mentions for Mirum Pharmaceuticals. Precigen's average media sentiment score of 1.20 beat Mirum Pharmaceuticals' score of 0.98 indicating that Precigen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mirum Pharmaceuticals 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Precigen 2 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor RYTM or PGEN?

In the previous week, Rhythm Pharmaceuticals and Rhythm Pharmaceuticals both had 6 articles in the media. Precigen's average media sentiment score of 1.20 beat Rhythm Pharmaceuticals' score of 0.71 indicating that Precigen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rhythm Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Precigen 2 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer PGEN or COGT?

In the previous week, Precigen had 3 more articles in the media than Cogent Biosciences. MarketBeat recorded 6 mentions for Precigen and 3 mentions for Cogent Biosciences. Precigen's average media sentiment score of 1.20 beat Cogent Biosciences' score of 0.74 indicating that Precigen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Precigen 2 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cogent Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Precigen (PGEN) Competitors

$5.86 +0.34 (+6.16%)

Closing price 06/26/2026 04:00 PM Eastern

Extended Trading

$5.82 -0.04 (-0.77%)

As of 06/26/2026 07:57 PM Eastern

Compare

PGEN vs. PTCT, CNTA, MIRM, RYTM, and COGT

Should you buy Precigen stock or one of its competitors? MarketBeat compares Precigen with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Precigen include PTC Therapeutics (PTCT), Centessa Pharmaceuticals (CNTA), Mirum Pharmaceuticals (MIRM), Rhythm Pharmaceuticals (RYTM), and Cogent Biosciences (COGT). These companies are all part of the "pharmaceutical products" industry.

How does Precigen compare to PTC Therapeutics?

Precigen (NASDAQ:PGEN) and PTC Therapeutics (NASDAQ:PTCT) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, earnings, institutional ownership, analyst recommendations, valuation and profitability.

PTC Therapeutics has a net margin of -22.58% compared to Precigen's net margin of -646.99%. Precigen's return on equity of 717.50% beat PTC Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Precigen	-646.99%	717.50%	58.48%
PTC Therapeutics	-22.58%	-362.45%	-6.76%

33.5% of Precigen shares are held by institutional investors. 41.4% of Precigen shares are held by insiders. Comparatively, 5.5% of PTC Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Precigen has a beta of 1.06, suggesting that its share price is 6% more volatile than the broader market. Comparatively, PTC Therapeutics has a beta of 0.56, suggesting that its share price is 44% less volatile than the broader market.

In the previous week, PTC Therapeutics had 11 more articles in the media than Precigen. MarketBeat recorded 17 mentions for PTC Therapeutics and 6 mentions for Precigen. Precigen's average media sentiment score of 1.20 beat PTC Therapeutics' score of 0.40 indicating that Precigen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Precigen	2 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
PTC Therapeutics	8 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Precigen presently has a consensus price target of $12.50, suggesting a potential upside of 113.31%. PTC Therapeutics has a consensus price target of $91.36, suggesting a potential upside of 8.20%. Given Precigen's higher probable upside, analysts clearly believe Precigen is more favorable than PTC Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Precigen	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
PTC Therapeutics	2 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.71

PTC Therapeutics has higher revenue and earnings than Precigen. PTC Therapeutics is trading at a lower price-to-earnings ratio than Precigen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Precigen	$9.68M	215.82	-$250.64M	-$1.18	N/A
PTC Therapeutics	$1.73B	4.05	$682.64M	-$2.33	N/A

Summary

Precigen beats PTC Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Precigen compare to Centessa Pharmaceuticals?

Centessa Pharmaceuticals (NASDAQ:CNTA) and Precigen (NASDAQ:PGEN) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, earnings, analyst recommendations, media sentiment and profitability.

Centessa Pharmaceuticals currently has a consensus target price of $41.33, suggesting a potential upside of 2.06%. Precigen has a consensus target price of $12.50, suggesting a potential upside of 113.31%. Given Precigen's stronger consensus rating and higher probable upside, analysts plainly believe Precigen is more favorable than Centessa Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Centessa Pharmaceuticals	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21
Precigen	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Centessa Pharmaceuticals has a net margin of 0.00% compared to Precigen's net margin of -646.99%. Precigen's return on equity of 717.50% beat Centessa Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Centessa Pharmaceuticals	N/A	-60.37%	-44.17%
Precigen	-646.99%	717.50%	58.48%

Centessa Pharmaceuticals has a beta of 1.11, suggesting that its share price is 11% more volatile than the broader market. Comparatively, Precigen has a beta of 1.06, suggesting that its share price is 6% more volatile than the broader market.

Centessa Pharmaceuticals has higher earnings, but lower revenue than Precigen. Centessa Pharmaceuticals is trading at a lower price-to-earnings ratio than Precigen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Centessa Pharmaceuticals	N/A	N/A	-$197.53M	-$1.79	N/A
Precigen	$9.68M	215.82	-$250.64M	-$1.18	N/A

In the previous week, Precigen had 2 more articles in the media than Centessa Pharmaceuticals. MarketBeat recorded 6 mentions for Precigen and 4 mentions for Centessa Pharmaceuticals. Precigen's average media sentiment score of 1.20 beat Centessa Pharmaceuticals' score of 0.73 indicating that Precigen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Centessa Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Precigen	2 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

82.0% of Centessa Pharmaceuticals shares are held by institutional investors. Comparatively, 33.5% of Precigen shares are held by institutional investors. 4.1% of Centessa Pharmaceuticals shares are held by company insiders. Comparatively, 41.4% of Precigen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Precigen beats Centessa Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

How does Precigen compare to Mirum Pharmaceuticals?

Mirum Pharmaceuticals (NASDAQ:MIRM) and Precigen (NASDAQ:PGEN) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, media sentiment, risk, valuation, institutional ownership, earnings, analyst recommendations and profitability.

Mirum Pharmaceuticals has higher revenue and earnings than Precigen. Mirum Pharmaceuticals is trading at a lower price-to-earnings ratio than Precigen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mirum Pharmaceuticals	$569.61M	13.23	-$23.36M	-$13.61	N/A
Precigen	$9.68M	215.82	-$250.64M	-$1.18	N/A

In the previous week, Precigen had 1 more articles in the media than Mirum Pharmaceuticals. MarketBeat recorded 6 mentions for Precigen and 5 mentions for Mirum Pharmaceuticals. Precigen's average media sentiment score of 1.20 beat Mirum Pharmaceuticals' score of 0.98 indicating that Precigen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mirum Pharmaceuticals	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Precigen	2 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Mirum Pharmaceuticals presently has a consensus price target of $139.80, suggesting a potential upside of 13.12%. Precigen has a consensus price target of $12.50, suggesting a potential upside of 113.31%. Given Precigen's higher possible upside, analysts clearly believe Precigen is more favorable than Mirum Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93
Precigen	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Mirum Pharmaceuticals has a beta of 0.5, suggesting that its stock price is 50% less volatile than the broader market. Comparatively, Precigen has a beta of 1.06, suggesting that its stock price is 6% more volatile than the broader market.

33.5% of Precigen shares are held by institutional investors. 8.3% of Mirum Pharmaceuticals shares are held by insiders. Comparatively, 41.4% of Precigen shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Mirum Pharmaceuticals has a net margin of -140.24% compared to Precigen's net margin of -646.99%. Precigen's return on equity of 717.50% beat Mirum Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mirum Pharmaceuticals	-140.24%	-11.28%	-3.84%
Precigen	-646.99%	717.50%	58.48%

Summary

Precigen beats Mirum Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

How does Precigen compare to Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals (NASDAQ:RYTM) and Precigen (NASDAQ:PGEN) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, earnings, analyst recommendations, media sentiment, dividends and profitability.

33.5% of Precigen shares are held by institutional investors. 5.9% of Rhythm Pharmaceuticals shares are held by insiders. Comparatively, 41.4% of Precigen shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Rhythm Pharmaceuticals has a net margin of -93.33% compared to Precigen's net margin of -646.99%. Precigen's return on equity of 717.50% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rhythm Pharmaceuticals	-93.33%	-203.25%	-44.99%
Precigen	-646.99%	717.50%	58.48%

Rhythm Pharmaceuticals presently has a consensus target price of $133.13, suggesting a potential upside of 21.20%. Precigen has a consensus target price of $12.50, suggesting a potential upside of 113.31%. Given Precigen's higher probable upside, analysts plainly believe Precigen is more favorable than Rhythm Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rhythm Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.83
Precigen	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Rhythm Pharmaceuticals has a beta of 1.91, meaning that its stock price is 91% more volatile than the broader market. Comparatively, Precigen has a beta of 1.06, meaning that its stock price is 6% more volatile than the broader market.

Rhythm Pharmaceuticals has higher revenue and earnings than Precigen. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Precigen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rhythm Pharmaceuticals	$189.76M	39.67	-$196.54M	-$3.13	N/A
Precigen	$9.68M	215.82	-$250.64M	-$1.18	N/A

In the previous week, Rhythm Pharmaceuticals and Rhythm Pharmaceuticals both had 6 articles in the media. Precigen's average media sentiment score of 1.20 beat Rhythm Pharmaceuticals' score of 0.71 indicating that Precigen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rhythm Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Precigen	2 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Precigen beats Rhythm Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Precigen compare to Cogent Biosciences?

Precigen (NASDAQ:PGEN) and Cogent Biosciences (NASDAQ:COGT) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, institutional ownership, dividends, risk, earnings, media sentiment, analyst recommendations and profitability.

Precigen has higher revenue and earnings than Cogent Biosciences. Cogent Biosciences is trading at a lower price-to-earnings ratio than Precigen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Precigen	$9.68M	215.82	-$250.64M	-$1.18	N/A
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.17	N/A

In the previous week, Precigen had 3 more articles in the media than Cogent Biosciences. MarketBeat recorded 6 mentions for Precigen and 3 mentions for Cogent Biosciences. Precigen's average media sentiment score of 1.20 beat Cogent Biosciences' score of 0.74 indicating that Precigen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Precigen	2 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cogent Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Precigen has a beta of 1.06, indicating that its stock price is 6% more volatile than the broader market. Comparatively, Cogent Biosciences has a beta of 0.34, indicating that its stock price is 66% less volatile than the broader market.

Precigen presently has a consensus price target of $12.50, suggesting a potential upside of 113.31%. Cogent Biosciences has a consensus price target of $43.73, suggesting a potential upside of 14.72%. Given Precigen's higher possible upside, equities analysts plainly believe Precigen is more favorable than Cogent Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Precigen	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.86

33.5% of Precigen shares are held by institutional investors. 41.4% of Precigen shares are held by insiders. Comparatively, 6.6% of Cogent Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Cogent Biosciences has a net margin of 0.00% compared to Precigen's net margin of -646.99%. Precigen's return on equity of 717.50% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Precigen	-646.99%	717.50%	58.48%
Cogent Biosciences	N/A	-104.27%	-54.64%

Summary

Precigen beats Cogent Biosciences on 12 of the 16 factors compared between the two stocks.

Get Precigen News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PGEN vs. The Competition

Export

Metric	Precigen	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.97B	$3.55B	$6.70B	$12.22B
Dividend Yield	N/A	2.25%	2.67%	6.12%
P/E Ratio	-4.97	21.56	25.76	24.17
Price / Sales	215.82	335.68	556.00	98.91
Price / Cash	N/A	137.38	46.99	54.37
Price / Book	97.67	8.34	10.77	6.35
Net Income	-$250.64M	$23.91M	$3.57B	$337.63M
7 Day Performance	21.58%	6.85%	3.17%	0.43%
1 Month Performance	33.18%	4.25%	1.86%	0.14%
1 Year Performance	312.68%	65.92%	34.39%	27.64%

Precigen Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PGEN Precigen	3.5343 of 5 stars	$5.86 +6.2%	$12.50 +113.3%	+309.8%	$1.97B	$9.68M	N/A	190	Positive News High Trading Volume
PTCT PTC Therapeutics	2.352 of 5 stars	$76.77 +2.2%	$91.36 +19.0%	+70.4%	$6.23B	$1.73B	N/A	1,410	Insider Trade High Trading Volume
CNTA Centessa Pharmaceuticals	1.7138 of 5 stars	$39.76 +0.1%	$41.33 +4.0%	N/A	$6.14B	$15M	N/A	200	Positive News Short Interest Decrease
MIRM Mirum Pharmaceuticals	2.2481 of 5 stars	$101.00 +1.7%	$139.80 +38.4%	+144.4%	$6.06B	$521.31M	N/A	140	Analyst Downgrade
RYTM Rhythm Pharmaceuticals	2.5083 of 5 stars	$89.70 +1.5%	$132.63 +47.9%	+78.8%	$6.06B	$189.76M	N/A	140	Insider Trade High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PGEN) was last updated on 6/27/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Precigen (PGEN) Competitors

PGEN vs. PTCT, CNTA, MIRM, RYTM, and COGT

How does Precigen compare to PTC Therapeutics?

Summary

How does Precigen compare to Centessa Pharmaceuticals?

Summary

How does Precigen compare to Mirum Pharmaceuticals?

Summary

How does Precigen compare to Rhythm Pharmaceuticals?

Summary

How does Precigen compare to Cogent Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PGEN vs. The Competition

Precigen Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Precigen (PGEN) Competitors

PGEN vs. PTCT, CNTA, MIRM, RYTM, and COGT

How does Precigen compare to PTC Therapeutics?

Is PGEN or PTCT more profitable?

Do insiders and institutionals hold more shares of PGEN or PTCT?

Which has more risk and volatility, PGEN or PTCT?

Does the media prefer PGEN or PTCT?

Do analysts prefer PGEN or PTCT?

Which has better earnings and valuation, PGEN or PTCT?

Summary

How does Precigen compare to Centessa Pharmaceuticals?

Do analysts prefer CNTA or PGEN?

Is CNTA or PGEN more profitable?

Which has more volatility and risk, CNTA or PGEN?

Which has higher earnings & valuation, CNTA or PGEN?

Does the media favor CNTA or PGEN?

Do institutionals & insiders hold more shares of CNTA or PGEN?

Summary

How does Precigen compare to Mirum Pharmaceuticals?

Which has preferable valuation & earnings, MIRM or PGEN?

Does the media favor MIRM or PGEN?

Do analysts prefer MIRM or PGEN?

Which has more volatility & risk, MIRM or PGEN?

Do institutionals and insiders hold more shares of MIRM or PGEN?

Is MIRM or PGEN more profitable?

Summary

How does Precigen compare to Rhythm Pharmaceuticals?

Do insiders and institutionals hold more shares of RYTM or PGEN?

Is RYTM or PGEN more profitable?

Do analysts prefer RYTM or PGEN?

Which has more risk and volatility, RYTM or PGEN?

Which has stronger earnings and valuation, RYTM or PGEN?

Does the media favor RYTM or PGEN?

Summary

How does Precigen compare to Cogent Biosciences?

Which has preferable earnings & valuation, PGEN or COGT?

Does the media prefer PGEN or COGT?

Which has more volatility and risk, PGEN or COGT?

Do analysts prefer PGEN or COGT?

Do insiders & institutionals believe in PGEN or COGT?

Is PGEN or COGT more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PGEN vs. The Competition

Precigen Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools